DEFA14A: Genmab to Acquire Merus for $8 Billion, Boosting Oncology Pipeline

Genmab A/S announced its intent to acquire Merus N.V. for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion, aiming to expand its late-stage oncology pipeline.

Summary

• Genmab A/S, through its wholly-owned subsidiary Genmab Holding II B.V. (Purchaser), will acquire Merus N.V. for $97.00 per common share in an all-cash tender offer.
• The total transaction value is approximately $8.0 billion.
• The offer price represents a premium of approximately 41% over Merus's closing stock price on September 26, 2025, and approximately 44% over its 30-day volume weighted average price.
• The acquisition is expected to accelerate Genmab's shift to a wholly-owned model, expanding revenue and driving sustained growth.
• Merus's lead asset, petosemtamab, an EGFRxLGR5 bispecific antibody, is in Phase 3 development for head and neck cancer and has two FDA Breakthrough Therapy Designations.
• Following the tender offer, Merus will become an indirect wholly-owned subsidiary of Genmab through back-end reorganization transactions, leading to delisting from Nasdaq and deregistration under the Exchange Act.
• Minority shareholders who do not tender their shares will receive the Offer Consideration or a fair price determined by a Dutch court in statutory buy-out proceedings, depending on tax rulings.
• The closing of the tender offer is subject to customary conditions, including a minimum acceptance of at least 80% of Merus common shares (reducible to 75% by Genmab), regulatory approvals, and Merus shareholder approval of post-closing governance and back-end transactions.
• Genmab has secured committed debt financing of approximately $5.5 billion from Morgan Stanley Senior Funding, Inc., and the transaction is not subject to a financing condition.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the substantial acquisition premium for Merus shareholders, the strategic fit of a promising late-stage asset (petosemtamab) with two Breakthrough Therapy Designations for Genmab, and clear financial projections for future growth and EBITDA accretion. The committed financing and unanimous board approvals further de-risk the transaction.

Positives

• The acquisition offers Merus shareholders a significant premium of approximately 41% over the closing stock price and 44% over the 30-day volume weighted average price.
• Genmab gains petosemtamab, a late-stage asset with two FDA Breakthrough Therapy Designations, which has shown compelling Phase 2 data with substantially higher overall response rate and median progression-free survival than standard of care in head and neck cancer.
• The transaction is expected to be accretive to Genmab's EBITDA by the end of 2029, with petosemtamab projected to achieve at least $1 billion in annual sales by 2029 and multi-billion-dollar annual revenue potential thereafter.
• The acquisition accelerates Genmab's strategic shift to a wholly-owned model, expanding and diversifying its revenue base and driving sustained growth.
• Genmab's strong financial position and committed debt financing ensure the transaction is not subject to a financing condition, providing certainty of funds.

Negatives

• Merus will be delisted from the Nasdaq Stock Market and deregistered under the Securities Exchange Act of 1934, ceasing its reporting obligations.
• Merus shareholders who do not tender their shares may be subject to statutory buy-out proceedings under Dutch law, where the amount per share would be determined by court proceedings, potentially differing from the Offer Consideration if certain tax rulings are not obtained.
• Outstanding Merus Options with an exercise price equal to or greater than the Offer Consideration will be canceled without consideration.

Risks

• Uncertainties exist regarding the timing and completion of the tender offer and proposed transactions.
• There are uncertainties as to the percentage of Merus shareholders tendering their shares in the tender offer and voting in favor of the proposed transactions at the extraordinary general meeting.
• The possibility of competing offers for Merus could arise.
• Various closing conditions for the tender offer or proposed transactions may not be satisfied or waived, including the failure to receive required regulatory approvals from governmental entities (or any conditions, limitations, or restrictions placed on such approvals).
• Disruption caused by the proposed transactions could make it more difficult to maintain relationships with employees, collaborators, vendors, and other business partners.
• Management's attention may be diverted from Merus's ongoing business operations due to the proposed transaction.
• Shareholder litigation in connection with the transactions contemplated by the Transaction Agreement may result in significant costs of defense, indemnification, and liability.
• Risks and uncertainties pertain to Merus's business, including those described in its Quarterly Report on Form 10-Q for the period ended June 30, 2025, and other SEC filings.
• Clinical trial outcomes, regulatory decisions, market entry of competitors, manufacturing/supply disruptions, reimbursement changes, and recommendations by medical organizations could impact the value of Merus's products.

Future Outlook

Genmab anticipates the potential for the initial launch of petosemtamab in 2027, subject to clinical results and regulatory approvals, and intends to broaden and accelerate its development into earlier lines of therapy. The acquisition is expected to be accretive to Genmab's EBITDA by the end of 2029, with petosemtamab projected to achieve at least $1 billion in annual sales by 2029 and multi-billion-dollar annual revenue potential thereafter. Genmab aims to achieve gross leverage of less than 3x within two years after the closing of the proposed transaction.

Management Comments

• Jan van der Winkel, Ph.D., President and Chief Executive Officer of Genmab, stated: "The proposed acquisition of Merus clearly aligns with our long-term strategy. It has the potential to significantly accelerate our evolution into a global biotechnology leader by providing durable growth for the company well into the next decade."
• Jan van der Winkel also commented: "Petosemtamab has the potential to be a transformational therapy for patients living with head and neck cancer. With our proven track record of success, both in clinical development and in commercialization, we are confident that we will be able to unlock the promise of petosemtamab."
• Bill Lundberg, M.D., President, Chief Executive Officer of Merus, remarked: "We are excited for the opportunity to join Genmab, a leader in antibody therapeutics, to further develop and bring petosemtamab to patients. Our two companies have a rich history of innovation with multiple approvals in the field of multispecific antibodies. We believe Genmab has the right vision and experience to advance petosemtamab in recurrent/metastatic head and neck cancer and beyond."
• Bill Lundberg added: "I’m immensely proud of the Merus team who have pioneered our foundational platform technologies to make better medicines and who have demonstrated – with an approved product and a product candidate, petosemtamab, in registrational studies – an ability to deliver on our promise to close in on cancer."

Industry Context

This acquisition signifies a strategic move within the oncology and biotechnology sectors, highlighting the increasing value placed on late-stage clinical assets, particularly in antibody therapeutics. Genmab's stated goal of accelerating its shift to a wholly-owned model reflects a broader industry trend among established biotech firms to internalize promising pipelines and capture more value from their innovations, rather than relying solely on partnerships. The focus on bispecific antibodies like petosemtamab underscores the continued innovation and investment in targeted therapies for cancer, especially for indications with high unmet needs like head and neck cancer.

Comparison to Industry Standards

• Petosemtamab's Phase 2 data, presented at ASCO 2025, showed an overall response rate and median progression-free survival that were 'substantially higher than standard of care' in head and neck cancer, indicating strong potential relative to existing treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions a risk of shareholder litigation in connection with the transactions contemplated by the Transaction Agreement, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Merus N.V. entered into a Foundation Support Agreement with Stichting Continuteit Merus (the Protection Foundation) concurrently with the Transaction Agreement. Under this agreement, the Protection Foundation agreed not to exercise its call option subscription rights to acquire preferred shares in Merus's capital during the term of the Transaction Agreement, and the Foundation Option Agreement will terminate upon the Closing.

Stakeholder Impact

• Shareholders: Merus shareholders are offered a significant premium for their shares, providing a clear exit opportunity. Those who do not tender may face a court-determined price in statutory buy-out proceedings.
• Employees: The filing mentions provisions for continuing employees regarding base salary, annual target cash bonus opportunity, and employee benefits for one year post-closing. Works council consultation processes are required.
• Customers/Partners: The acquisition could lead to changes in relationships with collaborators, vendors, and other business partners due to disruption, though Genmab aims to maintain these.
• Patients: The acquisition of petosemtamab, a late-stage asset for head and neck cancer, has the potential to bring a new transformational therapy to patients, with Genmab intending to accelerate its development.

Next Steps

• Purchaser will commence a tender offer for Merus common shares, anticipated to close by early in the first quarter of 2026.
• Merus will hold an extraordinary general meeting (EGM) to approve certain transactions related to the offer, including back-end transactions and the appointment of Purchaser designees to the board.
• Merus and Genmab will complete relevant works councils consultation processes.
• Following the closing of the tender offer, Merus and Genmab will effect a series of back-end transactions to make Merus a wholly-owned subsidiary of Genmab.
• Merus will be delisted from the Nasdaq Stock Market and deregistered under the Securities Exchange Act of 1934.
• Topline interim readout of one or both Phase 3 trials for petosemtamab is anticipated in 2026.
• Potential initial launch of petosemtamab is expected in 2027, subject to clinical results and regulatory approvals.
• Genmab plans to broaden and accelerate petosemtamab's development, including potential expansion into earlier lines of therapy.
• Genmab will provide its financial outlook for the full year 2026 in conjunction with its full year 2025 earnings report in February 2026.

Key Dates

Recommendation

The recommendation is a 'strong buy' for Merus shareholders due to the substantial cash premium offered (41% over recent closing price, 44% over 30-day VWAP), which represents a significant and immediate return on investment. For Genmab, the acquisition of a late-stage, breakthrough therapy asset like petosemtamab, with multi-billion-dollar revenue potential and expected EBITDA accretion, is a highly strategic move that strengthens its pipeline and accelerates its growth trajectory. The committed financing and unanimous board approvals further de-risk the transaction, making it a compelling opportunity for both sets of investors.

Keywords

Merus N.V., Genmab A/S, Acquisition, Tender Offer, Oncology, Biotechnology, Petosemtamab, Bispecific Antibody, Head and Neck Cancer, FDA Breakthrough Therapy Designation, SEC Filing, M&A, Pharmaceuticals, Clinical Stage, Nasdaq Delisting, Corporate Governance